MARKET

RCEL

RCEL

Avita Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.90
+0.14
+0.67%
Opening 10:21 04/14 EDT
OPEN
20.64
PREV CLOSE
20.76
HIGH
21.01
LOW
20.36
VOLUME
18.02K
TURNOVER
--
52 WEEK HIGH
34.95
52 WEEK LOW
5.20
MARKET CAP
510.38M
P/E (TTM)
-0.5045
1D
5D
1M
3M
1Y
5Y
BTIG Maintains a Buy Rating on Avita Medical (RCEL)
BTIG analyst Ryan Zimmerman maintained a Buy rating on Avita Medical (RCEL) today and set a price target of $41.00. The company's shares closed last
SmarterAnalyst · 2d ago
Acadia Healthcare (ACHC) Forms JV to Build Behavioral Health Units
Zacks.com · 03/31 17:22
15 RECELL® System Abstracts Accepted for Presentation at 53 Annual American Burn Association Meeting
Record Number of Accepted Abstracts Highlight Benefits of RECELL System and Reinforce Rapid Adoption by Surgeons to Advance Burn CareVALENCIA, Calif. and MELBOURNE, Australia, March 30, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH),...
GlobeNewswire · 03/30 21:01
AVITA Medical Says 15 Abstracts Highlighting Benefits Of RECELL Accepted For Presentation At American Burn Association Meeting
AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)))), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet
Benzinga · 03/30 20:02
Acadia Healthcare (ACHC) Gets Rating Upgrade Post U.K. Unit Sale
Zacks.com · 03/22 18:53
AVITA Medical picks seasoned industry executive as CFO
AVITA Medical ([[RCEL]] +4.0%) appointed 25-years industry veteran Michael Holder as CFO, effective Mar.22, responsible for overseeing the global finance, accounting, M&A, and investor relations functions and will be based in the company's Valencia office ...
Seekingalpha · 03/22 18:00
Acadia Healthcare (ACHC) Gets Rating Upgrade Post U.K. Unit Sale
Zacks.com · 03/22 17:03
BRIEF-Avita Medical, Inc. Names Michael Holder As Chief Financial Officer
reuters.com · 03/22 12:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RCEL. Analyze the recent business situations of Avita Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RCEL stock price target is 41.60 with a high estimate of 60.00 and a low estimate of 27.00.
EPS
Institutional Holdings
Institutions: 68
Institutional Holdings: 4.18M
% Owned: 17.13%
Shares Outstanding: 24.42M
TypeInstitutionsShares
Increased
14
288.29K
New
13
822.07K
Decreased
12
256.72K
Sold Out
4
131.56K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.49%
Pharmaceuticals & Medical Research
+0.93%
Key Executives
Non-Executive Chairman/Independent Director
Lou Panaccio
Chief Executive Officer/Executive Director
Michael Perry
Chief Financial Officer
Michael Holder
Chief Operating Officer
Kathy McGee
Chief Technology Officer
Andrew Quick
General Counsel
Donna Shiroma
Vice President - Operations
Terry Bromley
Other
Erin Liberto
Non-Executive Independent Director
Jeremy Cook
Vice President - Operations
William Marshall
Vice President/Director of Sales/Director of Marketing
Ross Saunders
Non-Executive Independent Director
Suzanne Crowe
General Manager
Lorraine Glover
Secretary
Gabriel Chiappini
Non-Executive Independent Director
Louis Drapeau
Vice President/Director of Marketing
Debbie Garner
No Data
About RCEL
AVITA Medical Inc., formerly AVITA Therapeutics, Inc., is a regenerative medicine company with a technology platform to address medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. Its technology provides treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. It has developed RECELL System, a product for the treatment of acute thermal burn injuries in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a way to treat severe burns that significantly reduces the amount of donor skin required. It can be used at the point of care alone or in combination with split-thickness skin autografts depending on the depth of the burn injury.

Webull offers kinds of AVITA Medical Inc stock information, including NASDAQ:RCEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCEL stock methods without spending real money on the virtual paper trading platform.